1077 related articles for article (PubMed ID: 11255440)
1. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
[TBL] [Abstract][Full Text] [Related]
2. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
3. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
Riemenschneider M; Lautenschlager N; Wagenpfeil S; Diehl J; Drzezga A; Kurz A
Arch Neurol; 2002 Nov; 59(11):1729-34. PubMed ID: 12433260
[TBL] [Abstract][Full Text] [Related]
6. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.
Tapiola T; Pirttilä T; Mehta PD; Alafuzofff I; Lehtovirta M; Soininen H
Neurobiol Aging; 2000; 21(5):735-40. PubMed ID: 11016543
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
9. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
10. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
Andreasen N; Vanmechelen E; Vanderstichele H; Davidsson P; Blennow K
Acta Neurol Scand Suppl; 2003; 179():47-51. PubMed ID: 12603251
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
13. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.
Kapaki E; Paraskevas GP; Zalonis I; Zournas C
Eur J Neurol; 2003 Mar; 10(2):119-28. PubMed ID: 12603286
[TBL] [Abstract][Full Text] [Related]
14. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR
Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986
[TBL] [Abstract][Full Text] [Related]
15. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
16. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
17. Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS).
Seppälä TT; Louhija UM; Appelberg B; Herukka SK; Juva K
Am J Geriatr Psychiatry; 2014 Sep; 22(9):908-16. PubMed ID: 23597931
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
19. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment.
Okonkwo OC; Mielke MM; Griffith HR; Moghekar AR; O'Brien RJ; Shaw LM; Trojanowski JQ; Albert MS;
Arch Neurol; 2011 Jan; 68(1):113-9. PubMed ID: 21220682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]